Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

MSD Ireland’s €1b facility investment achieves new milestone

0
SHARES

Opening of a new facility in Dunboyne, Co. Meath and expansion of MSD’s first vaccines operation outside of the US enables MSD Ireland to help address the demand for vaccines and medicines worldwide.

MSD Ireland’s €1b facility investment achieves new milestone

Credit: rafapress / Shutterstock.com

MSD Ireland’s new, state-of-the-art facility in Dunboyne, Co. Meath has opened. Additionally, the company has announced expansion of its Carlow site. In total, both projects represent an investment of over €1 billion.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

In total, both projects represent an investment of over €1 billion”

MSD Carlow runs as filling site for the launch and commercial supply of vaccines, biologics, and small molecule drug products. Opened in 2008, the facility was MSD’s first vaccines operation outside of the US. The new expansion will strengthen MSD’s global manufacturing capabilities to meet increased demand for MSD’s medicines and vaccines.

MSD Dunboyne in Co. Meath is MSD’s first biologics drug substance single use commercialisation facility. This recent investment will significantly accelerate the time it takes to bring a medicine to market, according to MSD Ireland.

As a result of the investment, 670 new jobs across both sites have been created. There are currently 100 active vacancies, covering key roles in sectors including engineering, science, manufacturing operations and quality.

“These two facilities will yield substantial enhancements to our manufacturing capabilities, enabling our global network to better address the always-evolving demand for vaccines and medicines worldwide,” remarked Sanat Chattopadhyay, Executive Vice President & President, Manufacturing Division, MSD.

MSD Ireland’s investment “reinforces the {Irish} Government’s commitment to balanced regional development, and further enhances Ireland’s global status in the pharmaceutical sector,” stated Taoiseach Leo Varadkar TD.

Share via
Share via